Pediatric Anaplastic Large Cell Lymphoma Treatment Strategies
Summary
Pediatric anaplastic large cell lymphoma (ALCL) is a rare but highly curable T-cell non-Hodgkin lymphoma, most often driven by anaplastic lymphoma kinase (ALK) translocations and marked by uniform expression of the CD30 antigen. Standard multi-agent chemotherapy protocols achieve long-term survival in 65–90 per cent of patients, yet around one-third experience relapse or refractory disease. Risk stratification now incorporates clinical features (such as small cell or lymphohistiocytic morphology, leukemic presentation and central nervous system involvement) and molecular measures including minimal disseminated disease (MDD) and minimal residual disease (MRD). Recent strategies aim to improve outcomes for high-risk patients while reducing long-term toxicities in low-risk groups. These include integration of targeted agents—anti-CD30 antibody-drug conjugates and ALK inhibitors—refined use of haematopoietic stem cell transplantation for salvage, and novel immunotherapies. Enhanced molecular monitoring supports early identification of patients requiring treatment intensification or de-escalation, and paves the way for truly individualised therapy.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Pediatric Anaplastic Large Cell Lymphoma Treatment Strategies publication trend
The graph below shows the total number of articles in pediatric anaplastic large cell lymphoma treatment strategies across all publications each year (not limited to Nature Index journals).
Technical terms
CD30: A cell-surface receptor uniformly overexpressed on ALCL cells, targetable by antibody-drug conjugates.
Anaplastic lymphoma kinase (ALK): A tyrosine kinase oncogene activated by chromosomal translocation in the majority of paediatric ALCL cases.
Antibody-drug conjugate: A therapy combining a monoclonal antibody specific for a tumour antigen with a cytotoxic payload.
Minimal disseminated disease (MDD) / Minimal residual disease (MRD): Low-level detection of tumour cells or fusion transcripts in blood or bone marrow, used for prognostic stratification.
Haematopoietic stem cell transplantation: A salvage approach using high-dose chemotherapy followed by infusion of stem cells to restore bone marrow function.
References
- Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. Cancers (2018).
- Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (2020).
- Brentuximab vedotin use in pediatric anaplastic large cell lymphoma. Frontiers in Immunology (2023).
- Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience. Cancer Medicine (2022).
- Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?. Cancers (2022).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.